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5Abstract 
Background: Self-reported food hypersensitivity remains unexplained in most cases. 
Abdominal symptoms, typically consistent with the irritable bowel syndrome (IBS), 
are common in patients with such unexplained, self-reported food hypersensitivity. 
The etiology is obscure. 
Aim: The overall objective of the present study was to investigate possible 
mechanisms of postprandial abdominal symptom generation. A main purpose was to 
explore whether and how ingestion of low-digestible carbohydrates act as abdominal 
symptom triggers in patients with unexplained, self-reported food hypersensitivity.
Main results: The findings can be summarized as follows:
In study I, fructose-sorbitol malabsorption evoked more symptoms in patients with 
unexplained, self-reported food hypersensitivity than in healthy controls. Alterations 
in intestinal gas production and secretion of so-called ileal brake hormones 
(glucagon-like peptide 1 (GLP-1) and peptide YY (PYY)) could not be demonstrated.
In study II, serum levels of chromogranin A (CgA) were found to be lower in patients 
with unexplained, self-reported food hypersensitivity than in healthy controls.
In study III, lactulose malabsorption evoked more symptoms in patients with 
unexplained, self-reported food hypersensitivity than in healthy controls. The 
symptoms could not be fully explained by symptom anticipation, because lactulose 
induced more symptoms than placebo (glucose). Associated alterations in intestinal 
gas production and rectal levels of prostaglandin E2 (PGE2) and microbial 
fermentation products could not be demonstrated.
In study IV, mechanisms of diarrhoea in a mouse model of food allergy were 
investigated. Changes within the jejunum were demonstrated in the food allergic 
mice, with development of muscular hypocontractility, increased levels of cytokines 
IL-4 and IL-6 and high numbers of mast cells.
6In study V, fecal levels of short-chain fatty acids (SCFA) were investigated, and the 
profile was different between patients with unexplained, self-reported food 
hypersensitivity and healthy controls. Increased proportions of butyric acid were 
demonstrated in the patient group, particularly in individuals with severe symptoms.
Conclusion: Taken together, the results suggest that intolerance to low-digestible 
carbohydrates plays an important role in abdominal symptom generation in patients 
with unexplained, self-reported food hypersensitivity. Disturbances of intestinal 
motility may contribute to gastrointestinal symptom development by increasing the 
amount of malabsorbed carbohydrates. Altered intestinal fermentation is a potential 
cause of the patients’ unexplained symptoms.
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1. Introduction 
1.1 Background 
Adverse reactions to food have probably always been recognized and feared by man 
[1]. Food hypersensitivity is common, but whereas up to 35% of the general 
population in Western countries suspect themselves to be food allergic [2], double-
blind placebo-controlled food challenge (DBPCFC) – the “gold standard” diagnostic 
test – can only verify reactions in response to specific foods in 1-2% [3;4]. The 
discrepancy between self-reported and medically confirmed food hypersensitivity 
(fig. 1) poses a great challenge for both patients and doctors, and a better 
understanding of the phenomenon is clearly needed.
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This thesis will focus on pathogenetic aspects of unexplained, self-reported food 
hypersensitivity in adults, with emphasis on gastrointestinal symptom development. 
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Although the proposed classification may seem logical and theoretically simple, 
diagnosing food hypersensitivity can be a demanding and complicated task in clinical 
practice. In fact, self-reported or perceived food hypersensitivity remains unexplained 
in most cases, despite extensive medical examinations. This group is conceivably 
“heterogenous”, but there are currently no convincing diagnostic methods to 
distinguish between different underlying etiologies. Various names have been applied 
to describe these ”problem patients”, such as ‘pseudo-allergy’ [8], ‘psychological 
food intolerance’ [9], ‘psychosomatic food adverse reactions’ [10], and ‘subjective 
food hypersensitivity’ [11].’Unexplained, self-reported food hypersensitivity’, albeit 
somewhat cumbersome, is presumably an informative and neutral term, and will be 
used in this thesis. 
1.3 Symptomatology 
Unexplained, self-reported food hypersensitivity may be regarded as a functional 
somatic syndrome [12], in which medically unexplained physical symptoms are 
ascribed or attributed by the patients to intake of certain foods. The clinical 
presentation may be different from that of patients with medically confirmed food 
allergy [13]. The symptoms are typically vague and diffuse, multisystemic and 
chronic, and commonly attributed to intake of staple foods, most often fruits, 
vegetables, cereals and milk [14;15]. Patients with unexplained, self-reported food 
hypersensitivity also report reacting to more food items than patients with confirmed 
food allergy [14]. Psychiatric comorbidity is common [16] and health-related quality 
of life is considerably impaired [17], at least in a specialist health care setting. 
Gastrointestinal symptoms seem to predominate [13], and the patients often complain 
of bloating, abdominal discomfort and disordered bowel habits (fig. 3).
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The abdominal symptoms are typically chronic or recurrent, and in most cases 
consistent with the criteria for irritable bowel syndrome (IBS) [15]. Vice versa, self-
reported food hypersensitivity is common in patients with IBS [20;21]. The IBS 
diagnosis labels a clinical phenotype, a constellation of symptoms that may have 
many causes. Although postprandial worsening of symptoms is not included in the 
current Rome consensus-based criteria for IBS [22], prospective symptom recording 
has shown that pain is temporally related to eating [23], and fasting may relieve the 
symptoms [24]. IBS due to possible food intolerance has recently been suggested as a 
separate entity [25], but whether patients with food-related IBS represent a discrete 
IBS subgroup or only differ from other IBS patients in terms of symptom 
interpretation, still remains unsettled. 
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1.3.1 Role of low-digestible carbohydrates 
The occurrence of food-related or postprandial symptoms in patients with functional 
gastrointestinal disorders typically involves many food items, and is therefore often 
interpreted as an expression of a generalized and unspecific sensitivity to meals, 
regardless of composition [20]. However, this may also reflect a propensity to react to 
categories of nutrients rather than specific epitopes. As such, carbohydrate-rich foods 
are particularly incriminated by the patients [14;15;20;21]. Indeed, a causal 
relationship between intake of heavily absorbable carbohydrates and chronic 
abdominal distress was suspected by physicians in the beginning of the last century – 
a phenomenon described as ‘Gährungsdyspepsie’ by Schmidt & Strasburger in 1901 
[26], and ‘Intestinal carbohydrate dyspepsia’ by Hurst & Knott in 1932 [27]. These 
conditions were once recognized by highly respected clinicians [28], but fell into 
disrepute in the early 1970s, seemingly because high fiber diets became fashionable 
around that time [29]. 
Low-digestible carbohydrates (LDC) can be defined as carbohydrates that are 
incompletely or not absorbed in the small intestine, and are totally or partly fermented 
in the large bowel [30]. The term LDC thus covers both complex carbohydrates 
(resistant starches and non-starch polysaccharides (dietary fibers)) [31] and a group 
of heavily absorbable short-chain carbohydrates denoted by Gibson & Shepherd as 
FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides and 
polyols) [32]. The usefulness of the term LDC may be debated, since individual LDC 
have different physiochemical characteristics and may differ in propensity to induce 
abdominal symptoms [33]. Nevertheless, the consequence of carbohydrate 
malabsorption seems to be a general, dose-dependent and additive phenomenon, 
seemingly reflecting some shared, group-based properties of all fermentable 
carbohydrates that escape small intestinal absorption [34]. Although there is evidence 
to suggest that ingestion of LDC is beneficial, LDC malabsorption seems to be poorly 
tolerated by some individuals [35-37]. The mechanisms behind such “symptomatic 
LDC malabsorption” or “LDC intolerance” are incompletely understood, and whether 
18
it plays a role in patients with unexplained, self-reported food hypersensitivity 
remains to be shown. 
1.4 Pathophysiology 
Although the cause of the abdominal symptoms in patients with unexplained, self-
reported food hypersensitivity is unknown, a disturbance in one or more of the 
control systems that regulate gut behaviour is probably implicated. Numerous 
signalling networks, residing both inside and outside the digestive tract, must interact 
in order to control and coordinate the complex actions of the gastrointestinal effector 
tissues (i.e. glands, musculature and vasculature) (fig. 4). 
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The gastrointestinal tract is recognized as the largest endocrine [38] and immune [39] 
organ in the body. The enteric nervous system contains as many neurons as the spinal 
cord [40], and the gut lumen harbours an exceedingly complex microbial flora [41]. 
In addition, myriads of neural and humoral signals constitute an important, bi-
directional communication route between the brain and the gastrointestinal tract, the 
so-called brain-gut axis or gut-brain axis [42]. There is an extensive interplay 
between the neurological, immunological, endocrinological and microbiological 
components of the gastrointestinal tract. Intake of food affects all of these systems. 
1.4.1 Role of the central nervous system 
Physicians tend to consider psychological explanations when no organic pathology 
can be demonstrated. However, no illness exists in a vacuum, and “psychological 
factors” are always present. It has been stated that “the gastrointestinal tract is the 
primary battleground for the conflicts between the psyche and the soma” (quoted in 
[43]). Indeed, digestive problems have been associated with psychological 
disturbances for many centuries [44] – but what are the links? 
There are at least three, not necessarily mutually exclusive, possibilities: 
Psychological disturbances may 1) cause or exacerbate the illness, 2) be a 
consequence of the illness, or 3) influence symptom experience and interpretation, 
and thus determine illness behaviour. 
Classical studies of fistulous patients, by Willam Beaumont (1785-1853) on Alexis 
St. Martin (1794-1880) [45] and by Stewart Wolf (1914-2005) on Tom [46], 
demonstrated a direct effect of emotions on gastric physiology. Ivan Petrovich Pavlov 
(1849-1936) discovered a ‘psychogenic secretion’ mechanism of the digestive glands 
in dogs [47], and Walter Bradford Cannon (1871-1945) evoked inhibition of 
intestinal motility in cats by scaring them [48]. Modern stress research has revealed 
important pathways involved in this “top-down” communication. Through the 
autonomic nervous system (ANS) and the neurohumoral hypothalamic-pituitary-
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adrenal axis (HPA axis), stress exerts several well-documented effects on both 
intestinal and extra-intestinal functions [49]. Emotions modulate the response and 
specific affective states may elicit different gastrointestinal reactions [50;51], 
conceivably providing an explanation why intestinal transit tends to be faster in 
anxious patients and slower in depressed patients [52]. Acute stress induces 
alterations in gastrointestinal motility and sensitivity that may cause or exacerbate 
symptoms of functional gastrointestinal disorders; e.g. impaired gastric emptying [53] 
and accommodation [54] in functional dyspepsia, and accelerated small intestinal 
transit [55;56] and increased distal colonic motility [57] in IBS. However, the effects 
of chronic stress, which is often more relevant in a clinical setting, is less well 
characterized, at least in man. 
Extensive activation of cognitive networks, due to so-called cognitive-emotional 
sensitization, has been proposed to play an important role in the pathophysiology of 
unexplained, self-reported food hypersensitivity [11]. Conceivably, such central 
mechanisms may explain the generation of numerous vague and diffuse symptoms 
from several organ systems [58]. An old case study deserves to be mentioned here, as 
an example of “central sensitization” [59]: A 54 year old woman with a diagnosis of 
functional diarrhoea, attributed by herself to the ingestion of pork meat, was 
examined with x-rays. First, minced pork meat was added to the barium solution, but 
the patient did not know. She experienced no symptoms and the films were 
completely normal. Second, the investigation was done only with the barium solution, 
but in addition, the patient ate a small slice of roast pork. She then experienced strong 
abdominal pain, and changes in the mucosa and motor activity of the small intestine 
were seen on the films. A similar study, using balloons to assess gastric and duodenal 
contractions in a woman with perceived milk intolerance, was reported by Graham et 
al. [60]. To repeat such experiments with more refined techniques, e.g. 
transabdominal ultrasonography [61], would be interesting – especially since the 
concept of cognitive-emotional sensitization is based mainly on theoretical 
considerations [58]. 
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Philippe Pinel (1745-1826), known as the father of modern psychiatry, stated that 
“the primary seat of insanity generally is in the region of the stomach and intestines” 
(quoted in [62]). Psychological disturbances may evolve secondary to abdominal 
abnormalities, both as direct [63] and indirect [64] consequences. An important 
example is duodenal ulcer disease, once regarded as a prototypical psychosomatic 
disorder, in which measures of psychological distress normalize following eradication 
of Helicobacter pylori infection [65]. Cortical affective information processing can 
be modulated by signals originating in the gastrointestinal tract and conveyed to the 
nucleus tractus solitarii, both through the vagus nerves and the sacral spinal nerves 
[66]. Indeed, electrical stimulation of the vagus nerve is a promising treatment 
modality for patients with major depressive disorder [67]. Although the view that 
psychopathology is a direct cause of gastrointestinal perturbations is both provocative 
and controversial, emerging evidence from animal studies supports the notion [68-
71]. However, little is still known about such “bottom-up” influences in man [72;73]. 
The possibility that psychopathology pertains to illness behaviour rather than the 
abdominal symptoms per se, has been suggested [74-77]. Far from all subjects 
suffering from functional gastrointestinal disorders decide to consult a physician [78], 
and “consulters” seem to represent a self-selected group, in which psychopathology is 
more common than in “non-consulters”. Accordingly, psychiatric comorbidity is 
common in patients with unexplained, self-reported food hypersensitivity referred to 
a specialist health care centre [16], but seemingly not in a community [79] or a 
primary health care [80] setting. However, differences in assessment of 
psychopathology may also play a role, since one population-based study 
demonstrated high prevalences of mood and anxiety disorders in subjects with self-
reported allergies using structured psychiatric interviews [81]. 
Importantly, psychological factors do not seem to be major predictors of neither 
intestinal nor extra-intestinal symptom severity in patients with unexplained, self-
reported food hypersensitivity [82]. Psychological disturbances may, however, be 
related to a tendency to interpret symptoms as signs of food hypersensitivity. Having 
difficulties in identifying and expressing feelings, and thus realizing and 
22
communicating psychological problems, conceivably influence attribution style [83]. 
Hence, psychological problems may be presented as food hypersensitivity [84]. 
Besides, somatic explanations are often regarded as more reputable than 
psychological explanations [85]. The belief that the problems are caused by food is 
probably reinforced and nourished by claims from media, alternative therapists and 
controversial scientists, as well as going through repeated medical investigations [86]. 
Simrén et al. [20] showed that IBS patients with anxiety had higher “food scores”, 
reflecting both the number of foods claimed to produce symptoms and the symptom 
severity, than IBS patients without anxiety. However, in a population-based study of 
subjects with IBS, Monsbakken et al. [21] found no correlation between numbers of 
food items related to abdominal symptoms and degree of psychopathology, as 
assessed by Hopkin Symptom Check List 10 scores. 
Hence, the role of psychological factors in unexplained, self-reported food 
hypersensitivity is obviously complex. The abdominal symptoms should not be 
regarded merely as “gutfelt emotions”, and a biopsychosocial approach is required. 
1.4.2 Role of the gut immune system 
In 1906 Baron von Pirquet (1874-1929) coined the term ‘Allergie’ to designate a 
‘changed reactivity’ induced by external agents (allos means ‘other’, and ergon
means ‘work’); originally a wide concept embracing both immunity and 
hypersensitivity [87]. The conventional Gell-Coombs classification recognizes four 
distinct types of immunological hypersensitivity reactions, denoted as types I, II, III 
and IV [88]. Type I responses are immediate reactions involving IgE-antibodies and 
mast cell degranulation, whereas type IV responses are delayed reactions involving T 
lymphocytes and cytokine production. Both mechanisms are of major clinical 
importance, but there is little evidence to suggest that type II (antibody-mediated 
cytotoxic hypersensitivity) or type III (immune complex-mediated hypersensitivity) 
responses are implicated in reactions towards foods [89]. 
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Classical IgE-mediated food allergy is characterized by rapid onset of typical 
symptoms (e.g. anaphylactic shock, asthma, angioedema, urticaria, pruritus, 
rhinorrhoea, vomiting, diarrhoea, abdominal pain), and positive sensitization tests 
(skin prick tests and/or systemic food-specific IgE antibodies) [90]. Conceivably, 
mechanisms involving IgE-antibodies and mast cell degranulation may also play a 
role in patients with unexplained, self-reported food hypersensitivity. As suggested 
by Lin et al. [91], local IgE-mediated reactions may be implicated. Indeed, an 
intestinal reaction resembling a typical food allergic response has been visualized in 
patients with unexplained, self-reported food hypersensitivity after intraduodenal 
adminstration of suspected allergens, using both endoscopic [92] and transabdominal 
[61] ultrasonography, as well as magnetic resonance imaging [93]. The intragastric 
allergen provocation test under endoscopic control (IPEC) [94], and the colonoscopic 
allergen provocation test (COLAP) [95], are examples of other potentially diagnostic 
methods. However, further validation is needed to establish the clinical utility of such 
provocation tests. 
Intriguingly, atopy may predispose for IBS. Atopy has been defined by the WAO [7] 
as ”a personal and/or familial tendency, usually in childhood or adolescence, to 
become sensitized and produce IgE antibodies in response to allergens, usually 
proteins”. ’Atopic IBS’ has recently been suggested as a new entity [96;97]. The 
view that ’atopic bowel’ may represent a discrete subgroup has been supported by 
Lillestøl et al. [98], who demonstrated that among patients with unexplained, self-
reported food hypersensitivity, subjects with atopy had higher counts of IgE-bearing 
mast cells in duodenal biopsies and higher values of intestinal permeability than 
subjects without atopy. Whether these observations have any clinical relevance 
requires further investigation, but mast cells coated with IgE antibodies are 
conceivably more reactive than mast cells without such ’arming’ [99]. 
Non-IgE-mediated food allergies are generally much more difficult to diagnose than 
IgE-mediated food allergies. Apart from celiac disease, such reactions are seldom 
recognized. Measurement of food-specific IgA and IgG levels to diagnose food 
hypersensitivity is controversial, as these antibodies appear to reflect a normal rather 
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than an allergic immune response to dietary antigen exposure [100]. Nevertheless, 
high levels of food-specific IgGs seem to be associated with gastrointestinal 
symptoms [101-103]. Lymphonodular hyperplasia – an endoscopic finding of 
uncertain clinical significance – may indicate delayed food allergy in children 
[104;105], and possibly also in adults [106;107]. The mucosal patch technique (MPT) 
[108], and measurement of B cell-activating factor (BAFF) [109] may provide future 
directions for detecting non-IgE mediated food allergies. 
The significance of immune-mediated food hypersensitivity in the pathophysiology 
of IBS remains elusive. Nevertheless, subclinical, low-grade, chronic inflammation 
seems to be of importance, especially in post-infectious forms of IBS [110]. The 
classical study of Chaudhary & Truelove, published in 1962 [111], is often 
recognized as the first description of post-infectious IBS. However, Stewart coined 
the term ‘post-dysenteric colitis’ in 1950 [112], and ‘post-acute infectious diarrhea’ 
was discussed and acknowledged as an etiological factor for functional diarrhoea at 
the 57th annual meeting of the American Gastroenterological Association in 1956 
[113]. Altered numbers of innate and adaptive immune cells, as well as changed 
levels of cytokines, have been demonstrated in blood samples and gut tissue 
specimens from patients with both post-infectious and non-postinfectious functional 
gastrointestinal disorders [114]. Animal studies have revealed important 
neuroimmune interactions with relevance for symptom generation [115]. 
Intestinal mast cells may be particularly involved in the pathophysiology of IBS 
[116]. These bone marrow-derived cells reside in the gut wall and are packed with 
granulae containing numerous chemical mediators, which are released upon 
activation. Although the classical activation of mast cells, by allergens crosslinking 
IgE antibodies bound to cell surface receptors on mast cells, provides a very powerful 
stimulus, mast cells are also activated by many other stimuli. Mast cells have direct 
contact with enteric nerve endings [117], and Santos et al. [118] demonstrated that 
mast cell mediators are released into the gut lumen during periods of cold pain-
induced stress. Furthermore, rodent studies have shown that the stressful event of 
maternal deprivation in early life leads to increased density of gut mucosal mast cells 
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[119]. Mast cell activation may also be implicated in other “hypersensitive” states, 
such as interstitial cystitis and asthma [120]. 
Hence, there is evidence to suggest that immunological mechanisms are implicated 
in the pathogenesis of unexplained, self-reported food hypersensitivity, at least in 
subsets of patients. As presently used diagnostic tests may be inadequate, further 
studies are needed. 
1.4.3 Role of the enteric nervous system 
In the mid-nineteenth century, large collections of nerve cells were discovered within 
the gut wall by Georg Meissner (1829-1905; plexus submucosus) and Leopold 
Auerbach (1828-1897; plexus myentericus) [121]. For a long time these ganglia were 
dismissed merely as parasympathetic relay stations. However, the enteric nervous 
system (ENS) contains both sensory and motor neurons, as well as interneurons and 
supportive glial cells, forming circuits that are able to process and integrate 
information independent of extrinsic innervation [122]. Hence, the ENS acts as a 
‘microcomputer’, popularly known as “the gut brain”, “the second brain” or “the 
brain gone south”. 
The ENS participates in the regulation of practically all gastrointestinal functions, and 
may thus play an important role in many digestive disorders, including adverse 
reactions to food. Interestingly, the gut seems to react to luminal threats (allergens, 
bacteria, viruses, parasites, toxins) in a stereotypical manner, suggesting that a 
general defense mechanism – a final common pathway – is involved in the response 
towards noxious substances. According to Wood [123], the ENS contains a neural 
pattern generator – an ‘enteric alarm program’ – that is turned on whenever certain 
material in the intestinal lumen is sensed and perceived as being foreign or harmful. 
Upon activation, a protective behaviour occurs, whereby the actions of the glands, 
musculature and vasculature are orchestrated by the ENS to eliminate the offending 
stimulus by rapid expulsion of the intestinal content, either rostrally (emesis) or 
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caudally (diarrhoea). Phylogenetically, this pre-programmed response is probably 
very old, and resembles other protective mechanisms, such as coughing and sneezing. 
Importantly, the enteric alarm program may also be activated by the central nervous 
system [123]. Intriguingly, the ultrasonographic findings by Arslan et al. [61;92;93] 
suggest that some patients with unexplained, self-reported food hypersensitivity are 
characterized by inappropriate activation of the enteric alarm program – either 
induced by peripheral (immunological) or central (cognitive-emotional) mechanisms. 
Alterations of gut motor and sensory functions seem to play an important role in the 
pathophysiology of IBS. Although gastrointestinal dysmotility and visceral 
hypersensitivity are complex phenomena, two recent studies suggest that ENS 
abnormalities may be particularly involved. First, studying full-thickness jejunal 
preparations, Törnblom et al. [124] demonstrated myenteric ganglionitis in patients 
with severe IBS, indicating that severe IBS may represent a mild form of enteric 
neuropathy. Second, Akbar et al. [125] observed increased numbers of TRPV1 
(transient receptor potential vanilloid type-1)-immunoreactive nerve fibers in mucosal 
rectosigmoid specimens from IBS patients – a possible neurobiological substrate for 
visceral hypersensitivity. These interesting findings are still preliminary observations, 
however, and further clarification is needed. 
Hence, unexplained, self-reported food hypersensitivity is probably not primarily a 
‘gut brain defect’. However, by means of its integrative functions, the ENS is likely 
involved in the generation of the patients’ gastrointestinal symptoms. 
1.4.4 Role of the enteroendocrine system 
Since Bayliss & Starling published their discovery of secretin in 1902 [126], a 
multitude of gut hormones has been characterized. Numerous enteroendocrine cells 
are dispersed among the absorbative enterocytes, and act as sensory transducers that 
“taste” the luminal content and translate this information into chemical messages. 
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These signals regulate several gastrointestinal functions and inform the brain about 
the state of the gut. 
Serotonin producing enterochromaffin cells (EC cells) constitute a major part of the 
enteroendocrine cell population. Indeed, most of the serotonin in the body is 
synthesized by these cells. In this regard, the name ‘enteramine’, as suggested by 
Erspamer in the 1930s, would have been a more appropriate term than ‘serotonin’ 
[127]. The EC cells have traditionally been conceived as “bottle-shaped” cells which 
empty their granular contents into the lamina propria. However, recent studies have 
revealed a neuron-like morphology [128] and ability of luminal secretion [129]. 
Serotonergic mechanisms seem to play an important role in functional gastrointestinal 
disorders [130]. Intriguingly, increased plasma serotonin concentrations have been 
demonstrated in patients with diarrhoea-predominant IBS following ingestion of a 
carbohydrate-rich meal [131], as well as after cold water intake [132]. However, as 
pointed out by Camilleri [133], peak serotonin levels were reached well after onset of 
the postprandial symptoms in both studies. Thus, the role of serotonin in unexplained, 
self-reported food hypersensitivity remains unclear. 
Apart from serotonin, abnormal levels of several regulatory gut peptides have been 
described in patients with functional gastrointestinal disorders. However, the results 
are generally inconsistent [134-137], and the clinical importance of the findings is 
still largely unknown [138]. Although some studies have investigated peptide release 
after different test meals, few investigators have attempted to relate the endocrine 
response with the potential of the test meal to induce postprandial symptoms. 
Chromogranins are stored and secreted together with amines and peptide hormones 
from the diffuse neuroendocrine system. These proteins serve as pro-hormones for a 
range of peptides with regulatory properties [139]. Interestingly, some of the peptides 
may be released into the gut lumen [140]. Fragments of chromogranins exert 
antimicrobial effects and may modulate gastrointestinal motility and sensitivity [141], 
but their potential role in functional gastrointestinal disorders is yet unknown. 
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Hence, disturbances of enteroendocrine pathways may play a role in patients with 
unexplained, self-reported food hypersensitivity. Specific nutrients stimulate 
different hormones, possibly explaining why some foods are better tolerated than 
others. However, studies adressing these aspects are still scarce. 
1.4.5 Role of the gut microbial flora 
The idea that the intestinal content can cause a number of physical and psychological 
ailments is very old [142]. Remedies to clean the bowel were used already in ancient 
Egypt, probably inspired by the peculiar behaviour of the ibis bird, as stated by 
Plinius (23-79 A.D.): “The bird which is called the ibis and which is a native of 
Egypt, by means of its hooked beak, laves the inside of his body by introducing water 
into the channel, by which it is especially necessary for health that the residuous food 
should be discharged” (quoted in [143]). Charles-Joseph Bouchard (1837-1915) 
wrote a book about ‘Auto-intoxication’ in 1894 [144], and the Royal Society of 
Medicine discussed the role of ‘Alimentary toxæmia’ at a symposium in 1913 [145]. 
Although these thoughts gradually fell into disrepute [146], new molecular methods 
to investigate the microbial ecology of the gut have been developed during the last 
decades [147], enabling scientists to revisit and renew old concepts [148]. 
The human body contains about 10 times more microbes than human cells, and the 
gut harbours around 1000 different bacterial species [149]. Regarding its size and 
metabolic activity, the “microbe organ” is comparable to the liver [150]. 
Communication between microbiota and their hosts has been denoted as “inter-
kingdom signalling”, and constitute a promising research area [151]. The gut 
microbial flora exerts several protective, structural and metabolic functions [41] and 
may be incriminated in a number of diseases, including allergy [152], adiposity [153] 
and autism [154]. However, our understanding of the complex gastrointestinal 
ecosystem is still in infancy. 
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Disturbances of the gut microbial flora, so-called “dysbioses” [155], are conceivably 
implicated in the pathogenesis of functional gastrointestinal disorders [156]. A 
number of epidemiological studies have demonstrated that gastrointestinal infections 
and antibiotic usage, factors that disturb the indigenous flora, may increase the risk of 
developing IBS [157]. Most clinical studies have focused on describing the 
composition of the fecal microbiota and testing the effect of more or less arbitrary 
“biotic” therapies (antibiotics, probiotics, prebiotics, synbiotics) in patients with IBS. 
Less effort has been put on mechanistic studies, i.e. understanding what the microbes 
do and how this may contribute to symptom generation [158]. 
The assumed primary function of the gut microbial flora is decomposition of 
otherwise indigestible food components by means of fermentation [159]. This is a 
critical part of the digestive process, not only in plant-eating animals (herbivores), but 
also in humans (omnivores). If nutrients entering the colon are not fermented by 
bacteria, calories will be lost in feces, together with water and electrolytes. Thus, the 
role of the colon as a ‘salvage organ’ [160] is dependent on microbes. In return, the 
microbes are offered stable food supplies and optimal housing conditions for growth 
and reproduction. Intestinal fermentation yields both gases (e.g. hydrogen, methane, 
carbon dioxide) and short-chain fatty acids (SCFA; e.g. acetic, propionic and butyric 
acids), and should normally take place mainly in the proximal colon. Excessive, 
impaired or altered fermentation, as well as fermentation in other parts of the 
gastrointestinal tract (i.e. small intestine, rectum), may cause symptoms. Such 
problems have been denoted as ‘enterometabolic disturbances’ by Hunter [161], and 
may be involved in the pathogenesis of meal-related, functional gastrointestinal 
disorders. 
Hence, the “microbe organ” is still largely a terra incognita. Disturbances of the 
gut microbial flora, and consequently, intestinal fermentation, may play a role in 
gastrointestinal symptom development in patients with unexplained, self-reported 
food hypersensitivity. 
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2. Aims of the study 
The overall objective of the present study was to investigate possible mechanisms of 
postprandial abdominal symptom generation. A main purpose was to explore whether 
and how ingestion of LDC act as abdominal symptom triggers in patients with 
unexplained, self-reported food hypersensitivity. 
The specific aims of the papers included in the thesis were: 
I  To assess the role of fructose-sorbitol intolerance in patients with unexplained, 
self-reported food hypersensitivity, and evaluate whether the abdominal 
symptoms are related to excessive intestinal gas production or disturbances of 
ileal brake hormone secretion. 
II To explore whether patients with unexplained, self-reported food 
hypersensitivity have abnormal circulating levels of CgA. 
III To evaluate whether abdominal symptoms induced by lactulose ingestion in 
patients with unexplained, self-reported food hypersensitivity are related to 
intestinal fermentation, measured as intestinal gas excretion in breath samples 
and microbial fermentation products in rectal dialysates, or merely reflect 
symptom anticipation. 
IV To investigate mechanisms of diarrhoea in a mouse model of food allergy. 
V To explore whether the gut microbial flora has abnormal functions in patients 
with unexplained, self-reported food hypersensitivity. 
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3. Materials and methods 
An overview of the procedures will be outlined in the following section. 
Methodological details are described in the separate papers. 
3.1 Clinical studies 
3.1.1 Patients 
Consecutive patients with abdominal symptoms refereed to Haukeland University 
Hospital for investigation of self-reported food hypersensitivity were asked to 
participate in the study. All patients underwent an extensive, multidisciplinary 
investigation program by a devoted team of clinical specialists (the ”MAI group”; 
Norwegian abbreviation for ’Matallergi og -intoleranse’; ’Food allergy and 
intolerance’). Food allergies were excluded by allergological examinations, including 
careful history-taking and evaluation of immunological sensitization towards 
suspected food items by using skin-prick tests and measurements of food-specific IgE 
antibodies. Successive dietary trials were performed by a dietician, and began with an 
open elimination of the most strongly suspected food item from the diet for 2–3 
weeks. If this led to symptomatic improvement, an open provocation test was 
performed, and if positive, a DBPCFC with the same food item was done. Organic 
gastrointestinal diseases were excluded by gastroenterological examinations, 
including upper endoscopy with duodenal biopsies (to diagnose celiac disease), and 
measurement of intestinal permeability. Colonoscopy was performed when indicated, 
i.e. if fecal calprotectin was elevated and/or if inflammatory bowel disease was 
suspected clinically. Initially, tests to diagnose lactase deficiency were performed 
routinely, but due to the low diagnostic yield [162], the test was soon abandoned. 
Exclusion criteria were age below 18 years, pregnancy or lactation, prior use (in the 
past 4 weeks) of antibiotics, confirmed food allergy and organic gastrointestinal 
diseases.
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3.1.2 Controls 
Healthy volunteers were recruited among the hospital staff and students at the 
University of Bergen. They were included if they considered themselves to be 
healthy, and were not otherwise examined. They were excluded if they had used 
antibiotics during the previous 4 weeks. 
3.1.3 Questionnaires 
IBS was diagnosed according to the Rome II criteria as follows [163]: 
”At least 12 weeks, which need not be consecutive, in the preceding 12 months of 
abdominal discomfort or pain that has two of three features: 
(1) Relieved with defecation; and/or 
(2) Onset associated with a change in frequency of stool; and/or 
(3) Onset associated with a change in form (appearance) of stool.”
Severity of habitual abdominal symptoms was assessed by using questionnaires 
developed by Kane et al. [18] (study I) and Francis et al. [19] (study III & V). 
Severity of symptoms following ingestion of carbohydrates was quantified by using 
scoring scales modified from Farup et al. [162] (study I & III). 
3.1.4 Breath tests 
Hydrogen and methane breath tests are based on the fact that there is no source for H2
or CH4 in man other than microbial fermentation [164]. These gases are thus 
exclusively produced within the gastrointestinal system and a certain proportion 
(approximately 60% [165]) is excreted into exhaled air from the lungs. As outlined in 
a recent consensus document [166], certain precautions prior to the procedure are 
neccessary, such as fasting and avoiding use of tobacco. In the present study, exhaled 
H2 and CH4 were assessed before and every 15 minutes for 3 hours after ingestion of 
a carbohydrate solution by using breath collection bags and a gas chromatograph 
from Quintron Instrument Company (WI, USA). In study I & II, a mixture of 25 g 
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fructose and 5 g sorbitol in 250 ml tap water was ingested. In study III, mixtures of 
10 g lactulose in 120 ml tap water and 10 g glucose in 120 ml tap water were 
ingested. Osmolality was measured in the carbohydrate solutions as follows (Fiske® 
Microsample Osmometer, Advanced Instruments Inc., Norwood, MA, USA): 
fructose-sorbitol – 714 mOsm/kg H2O; lactulose – 324 mOsm/kg H2O; glucose – 572 
mOsm/kg H2O. 
3.1.5 Blood samples 
Blood samples were analysed for GLP-1 and PYY at the Department of Biomedical 
Sciences, University of Copenhagen, Denmark (study I) and for CgA at the 
Department of Biological and Medical Psychology, University of Bergen, Norway 
(study II). The specimens were obtained by drawing blood through an intravenous 
cannula, allowing the subjects to acclimatize to the study protocol prior to 
commencing assessments. The importance of such a ’recovery period’ has recently 
been emphasized by Chandarana et al. [167]. 
3.1.6 Rectal dialysis 
In study III, in vivo rectal dialysis was employed. The principle behind the method 
was originally described in 1961 by Wrong et al. [168], and the technique has 
previously been used to examine a variety of clinical conditions, including 
assessments of SCFA [169], D- and L-lactate [170] and PGE2 [171]. As shown by 
Lauritsen et al. [171], a duration of 4 hours is required for the dialysate to reach 
equilibrium with the surrounding fluid. The dialysis bags (fig. 5) were made of 
cellulose membrane tubing (Visking code DVT12000.01.000; molecular weight cut-
off 12-14 kDa; Medicell International Ltd., London, UK), prepared by heating the 
membrane in a solution of 2% NaHCO3 and 1 mM EDTA at +80°C for 30 minutes. 
Twelve cm long dialysis bags were tied off and filled with 4 ml Rheomacrodex®
(10% dextran (mean molecular weight 40 kDa) in saline; Meda A/S, Norway). 
Dialysates were analysed for SCFA at the Department of Microbiology, Tumor and 
Cell Biology, Karolinska Institutet, Sweden, and for D- and L-lactate and PGE2 at the 
Institute of Medicine, University of Bergen, Norway. 
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3.1.7 Fecal samples 
Stool collection may be challenging [172]. In study V, special plastic boxes were 
used (reg. codes 257077 and 257078, Coperate Express, Oslo, Norway). The upper 
edge of these boxes is equipped with a rim, making it easy to hold the box with both 
hands while defecating directly into it. The subjects were carefully instructed on how 
to perform this procedure, and were told to store the boxes at –20° C immediately 
after voiding feces. Stool samples were analysed for SCFA at the Department of 
Microbiology, Tumor and Cell Biology, Karolinska Institutet, Sweden. 
35
3.2 Experimental animal study 
In study IV, an experimental mouse model of food allergy developed by Vaali et al. 
[173] was employed. A unique feature of this model is that no immunostimulatory 
adjuvants are used to induce the allergic response (adjuvants have been referred to by 
Charles A. Janeway Jr. (1943-2003) as “the immunologist’s dirty little secret”
(quoted in [174])). The protocol is outlined in figure 6. 
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Briefly, Balb/c mice are epicutaneously sensitized with ovalbumin (allergic mice) or 
sham-sensitized with saline (controls). After an immunological maturation period, 
needed to produce ovalbumin-specific IgE antibodies, both groups are thereafter 
challenged with intragastric administration of ovalbumin. If successful, the 
ovalbumin-sensitized mice, but not the sham-sensitized mice, develop diarrhea after 
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the sixth intragastric challenge, and thereafter repeatedly within 20 to 60 minutes 
after each intragastric challenge. 
In study IV, the mice were sacrificed 1 hour after the tenth intragastric challenge. 
Segments of jejunum were then obtained and the in vitro contractility of the circular 
musculature towards carbachol was studied in organ bath (fig. 7). Jejunal smooth 
muscle layer thickness and mucosal mast cell protease-1 (MMCP-1) positive cell 
density were assayed histologically. Serum MMCP-1 and immunoglobulins were 
measured by ELISA at the Institute of Medicine, University of Bergen, Norway, 
whereas mRNA expressions of IFN-, IL-4, IL-6 and TGF-1 from jejunal and ileal 
tissue segments were analyzed with quantitative real-time PCR at the Wihuri 
Research Institute, Helsinki, Finland. 
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3.3 Ethics 
The clinical studies (I, II, III, V) were approved by the Regional Committee for 
Medical Research Ethics and conducted according to the Declaration of Helsinki. The 
animal study (IV) was approved by the Norwegian Animal Research Authority and 
conducted according to the European Convention for the Protection of Vertebrates 
Used for Scientific Purposes. 
3.4 Statistics 
Data were analyzed using Graphpad Prism version 5 (Graphpad Software Inc., San 
Diego, CA, USA) and SPSS (version 14, SPSS Inc., Chicago, IL, USA). P-values less 
than 5% were considered as statistically significant. Details are described in the 
separate papers. 
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4. Results 
4.1 Study I 
Eighteen patients with unexplained, self-reported food hypersensitivity and 15 
healthy volunteers of similar age, gender and body mass index were included in the 
study. Sixteen of the 18 patients (89%) had IBS according to the Rome II criteria and 
habitual symptom scores were higher in patients than in controls (P < 0.0001). 
Following ingestion of a mixture of 25 g frucose and 5 g sorbitol, carbohydrate 
malabsorption, as defined by breath tests criteria, was demonstrated in 61% of the 
patients and in 73% of the controls. Nevertheless, the patients experienced 
significantly more symptoms following carbohydrate challenge, and 78% of the 
patients claimed that the challenge replicated their habitual gastrointestinal 
complaints. Patients classified as ‘malabsorbers’ experienced more symptoms than 
patients classified as ‘absorbers’ (P = 0.03). No significant differences in gas 
excretion or GLP-1 and PYY levels were found between patients and controls or 
between symptomatic and asymptomatic carbohydrate malabsorbers. A weak 
correlation between hydrogen excretion and PYY levels was demonstrated in non-
producers of methane. 
4.2 Study II 
The same subjects as in study I were investigated. Serum levels of CgA were 
significantly lower in patients with unexplained, self-reported food hypersensitivity 
than in healthy controls at baseline (P = 0.005), and after 60 and 180 minutes 
following fructose-sorbitol ingestion (P = 0.007 and P = 0.004, respectively). In 
addition, serum levels of CgA fell significantly from baseline to 180 minutes 
following fructose-sorbitol ingestion (P = 0.04 for patients and P = 0.01 for controls). 
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4.3 Study III 
Twenty-seven patients with unexplained, self-reported food hypersensitivity and 9 
healthy volunteers of similar age, gender and body mass index were included in the 
study. Twenty-five of the 27 patients (93%) had IBS according to the Rome II criteria 
and habitual symptom scores were higher in patients than in controls (P < 0.0001). 
Patients were examined twice, with ingestion of 10 g lactulose and 10 g glucose, 
given in random order and in a double-blinded fashion. Controls were examined only 
once, with 10 g lactulose. In patients, symptom scores following lactulose ingestion 
were significantly correlated to habitual symptom scores (r = 0.6, P = 0.001), and 
were significantly higher than after glucose ingestion (P = 0.01). Symptom scores 
following both lactulose and glucose ingestion were significantly higher in patients 
than in controls (P = 0.0007 and P = 0.03, respectively). Levels of SCFA, lactate and 
PGE2 in rectal dialysates were not significantly different after lactulose and glucose, 
or between patients and controls. Hydrogen excretion was not correlated with 
symptom scores. 
4.4 Study IV 
Eight Balb/c mice were sensitized towards ovalbumin (food allergic mice) and 5 
Balb/c mice were sham-sensitized with saline (control mice). Both groups were 
challenged with repeated intragastric administrations of ovalbumin, whereby 
diarrhoea developed in 5 of the 8 food allergic mice. Hypocontractility of the jejunal 
circular musculature in response to carbachol stimulation was demonstrated in the 
food allergic mice with diarrhoea. Food allergic mice had higher jejunal mRNA 
levels of cytokines IL-4 and IL-6 and increased numbers of jejunal mast cells 
compared to controls. Jejunal smooth muscle layer thickness and jejunal mRNA 
levels of IFN- and TGF-1 did not differ between the groups. Serum levels of 
ovalbumin-specific IgE antibodies were significantly correlated with numbers of 
jejunal mast cells (r = 0.879, P < 0.0001), as well as serum levels of MMCP-1 (r = 
0.863, P < 0.0001). 
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4.5 Study V 
Thirty-five patients with unexplained, self-reported food hypersensitivity and 15 
healthy volunteers of similar age, gender and body mass index were included in the 
study. Thirty-four of the 35 patients (97%) had IBS according to the Rome II criteria. 
Fecal concentrations and excretions (output) of SCFA were similar in patients and 
controls, but n-butyric acid comprised a higher (P = 0.035) and acetic acid a lower (P
= 0.012) proportion of total SCFA concentration in patients compared to controls. 
There were no significant correlations between habitual symptom scores and 
concentrations or excretions of individual or total SCFA, but the proportion of n-
butyric acid was significantly higher in patients with severe symptoms compared to 
patients with moderate symptoms (P = 0.016). 
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5. General discussion 
A main purpose of the present study was to explore whether and how ingestion of 
low-digestible carbohydrates (LDC) act as abdominal symptom triggers in patients 
with unexplained, self-reported food hypersensitivity. LDC provocation tests were 
thus used as tools to induce and study the pathophysiology of gastrointestinal 
symptoms, and this approach proved to be useful. In study I, intake of a heavily 
absorbable fructose and sorbitol mixture evoked more symptoms in patients than in 
controls, and although the prevalence of malabsorption was similar in these groups, 
patients classified as ‘malabsorbers’ experienced more symptoms than patients 
classified as ‘absorbers’. In study III, ingestion of the unabsorbable carbohydrate 
lactulose induced symptoms that resembled the patients’ habitual symptoms, both 
qualitatively and quantitatively, and these post-test symptoms were significantly 
worse than after ingestion of the easily absorbable carbohydrate glucose. The LDC-
induced symptoms were associated with fermentation as assessed by measurements 
of intestinal gas excretion in breath samples. However, the mechanisms whereby 
LDC malabsorption causes symptoms were not fully explained. Taken together, study 
I & III thus suggest that LDC malabsorption is an important prerequisite for LDC-
induced symptoms, but the pathophysiology remains unclear. 
Tolerance to LDC is influenced by a number of factors, including characteristics of 
the meal, the individual and the gut microbial flora (fig. 8) [30]. Some of these factors 
will be discussed in the following text, based on the results of study I-IV and the 
findings of others. 
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Disturbances of motility in the upper digestive tract may impair LDC absorption, and 
aspects of gastrointestinal motor function were specifically adressed in study I & IV. 
In study I, the so-called ‘ileal brake response’ was investigated. The aim was to 
explore whether altered blood levels of the ileal brake hormones glucagon-like 
peptide 1 (GLP-1) and peptide YY (PYY) could be related to symptoms following 
ingestion of a poorly absorbable mixture of fructose and sorbitol. The findings did not 
support this view, however, since similar responses were demonstrated between 
patients and controls, and among symptomatic and asymptomatic carbohydrate 
malabsorbers. Study I was originally planned to assess orocecal transit of the 
fructose-sorbitol mixture as well, by using a scintigraphic method developed by Read 
et al. [175]. Briefly, 20 MBq 99mTc-albumin-colloid (Nanocoll®) was added to the 
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carbohydrate solution, and radioactivity was measured every 15 minutes for 3 hours 
with a hand-held gammaprobe (codes 6150AD-17 (probe) and 6150AD-2 (dose rate 
meter); Automess GmbH, Ladenburg, Germany) positioned over a point 2 cm medial 
to the right anterior superior iliac spine, corresponding to the surface of the usual 
place of the cecum. However, this method proved to be inaccurate, and was therefore 
left out. Although study I failed to demonstrate altered functions of the endocrine L-
cells in patients with unexplained, self-reported food hypersensitivity, GLP-1-based 
treatments for patients with IBS have recently been suggested [176;177]. 
Furthermore, ileal brake hormones exert effects mainly on upper gastrointestinal 
motility, and altered secretions of GLP-1 and PYY may therefore be particularly 
involved in the pathophysiology of functional dyspepsia [178]. L-cell derived 
peptides may thus play a role in patients with functional gastrointestinal disorders that 
ought to be further elucidated. 
An additional assessment of the blood samples obtained in study I was subsequently 
published as a ‘Letter to the Editor’ in Scandinavian Journal of Gastroenterology
(study II). Serum levels of chromogranin A (CgA) were analyzed and found to be 
significantly lower in patients with unexplained, self-reported food hypersensitivity 
than in healthy controls. Fragments of CgA exert antimicrobial effects and may 
modulate gastrointestinal motility and sensitivity [141], but the clinical significance 
of low systemic levels of CgA remains to be clarified. Follow-up studies with 
emphasis on EC cell abnormalities [179] have been initiated, and will hopefully gain 
further insights into the potential role of CgA in patients with unexplained, self-
reported food hypersensitivity. 
In study IV, in vitro contractility of the circular smooth muscle layer was investigated 
in jejunal segments obtained from mice. The main purpose of the study was to 
investigate whether food allergy induces a non-allergen-specific disturbance of 
intestinal motility. A stable derivative of acetylcholine was used to test this 
hypothesis, since acetylcholine is the prinicipal neurotransmitter involved in intestinal 
smooth muscle contraction. The study demonstrated that specimens obtained from 
food allergic mice were less responsive to carbachol than specimens obtained from 
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control mice. This reduction of smooth muscle contractility was associated with – and 
possibly a consequence of [180] – increased levels of cytokines IL-4 and IL-6. 
Hypocontractility of the jejunal circular muscle layer conceivably causes a loss of 
intestinal tone, leading to a decrease of the intraluminal resistance and an increase of 
the flow of intestinal content [181]. As such, the finding may have a bearing to the 
reactions induced by intestinal provocation with suspected allergens observed by 
Arslan et al. [61;93] in patients with unexplained, self-reported food hypersensitivity. 
Intriguingly, postprandial loss of tonic motor activity of the intestinal musculature has 
recently been proposed to play a major role in symptom generation in patients with 
functional gastrointestinal disorders [182]. Decrease of intestinal tone may favour 
luminal filling by gas and fluid, and hence cause symptoms [182]. In addition, such 
changes may impair digestion and absorption of nutrients, especially of those that are 
heavily absorbable, thereby increasing the entrance of undigested and unabsorbed 
food residues, particularly LDC, into the colon [183;184]. 
In study IV, numbers of jejunal mast cells were increased in the food allergic mouse 
group. Intriguingly, similar findings have been reported in patients with diarrhoea-
predominant irritable bowel syndrome [185]. Activation of intestinal mast cells may 
be implicated in LDC-induced abdominal symptoms in at least two ways. First, 
psychological stress may accelerate small intestinal transit [55;56] via mast cell 
degranulation [118], and thereby increase LDC malabsorption. Second, unabsorbed 
LDC may serve as an osmotic load, drawing fluid into the intestinal lumen, as well as 
triggering mast cell degranulation [186]. This may explain why LDC accelerate small 
bowel transit [187;188], and thus influence symptom generation [189]. The intestinal 
motor response to luminal hyperosmolarity seems to be individual [190], and is 
conceivably exaggerated in patients with functional gastrointestinal disorders [191]. 
Subjects with increased numbers of ‘IgE armed’ mast cells may be particularly 
exposed [98;99]. Induction of airway symptoms by mannitol inhalation in patients 
with exercise-induced bronchoconstriction (EIB) involves mast cell activation [192]. 
Whether degranulation of intestinal mast cells plays a similar role in gastrointestinal 
symptom development following LDC ingestion in patients with unexplained, self-
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reported food hypersensitivity, deserves to be investigated. Indeed, IBS has 
previously been conceptualized as “asthma of the gut” [193]. 
Abnormalities of gastrointestinal motor function may affect the amount of LDC 
malabsorbed, and thus lower the threshold at which the symptoms occur [194]. 
Nevertheless, such alterations may not fully explain why ingestion of lactulose causes 
more symptoms in patients with unexplained, self-reported food hypersensitivity than 
in healthy controls, since lactulose is malabsorbed completely in both groups. 
Disturbances at the level of intestinal fermentation may be implicated. LDC serve as 
substrates for microbes producing gases and short-chain fatty acids (SCFA), and such 
fermentation products may be involved in abdominal symptom generation. 
In study I & III, intestinal gas production following LDC ingestion was evaluated by 
measurements of intestinal gas excretion in breath samples. Although this method is a 
useful technique to assess overall changes in fermentation, it gives relatively little 
information about qualitative and quantitative changes within the viscera [195]. The 
lack of correlation between symptom scores and gas excretion in study I & III may 
reflect such limitations. However, as demonstrated by Morken et al. [196], intestinal 
gas volumes as quantified by scoring plain abdominal radiographs were not 
correlated with symptoms following lactulose ingestion, either. Despite certain 
studies [197;198], the overall impression thus seems to be that excessive intestinal 
gas production is not the main culprit of the symptoms [199]. Impaired gas transit and 
enhanced sensitivity to gaseous distension may play a role [200;201]. However, such 
problems could not explain the response to fructose-sorbitol malabsorption in a study 
by Evans et al. [202]. 
Gas is tolerated less well in the small intestine than in the large bowel [203], and 
small intestinal bacterial overgrowth (SIBO) may cause excessive gas production in 
the small intestine [204]. Although study I & III were not primarily designed to detect 
SIBO, the occurrence of so-called ’early positive breath tests’, i.e. a rise in hydrogen 
excretion above baseline of more than 20 parts per million (ppm) within 90 minutes, 
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was similar in patients and controls in both studies. The validity of this criterion is 
debated, especially since rapid orocecal transit may cause ’false’ early positive breath 
tests [205]. Simultaneous assessment of orocecal transit by use of scintigraphy can be 
of help to distinguish between SIBO and rapid orocecal transit [206]. Indeed, such a 
method was employed as a preliminary study in six patients with unexplained, self-
reported food hypersensitivity, and confirmed that the large bowel was the source of 
hydrogen production in all cases [unpublished data]. Unfortunately, however, this 
combined breath test and scintigraphy assessment had to stop due to logistical 
reasons. The role of SIBO in patients with IBS is currently debated [207], and even 
the demonstration of excessive hydrogen excretion (>20 ppm above baseline 
concentration) in response to 10 g glucose in 3 patients in study III, may be explained 
by rapid orocecal transit [208]. 
Methane (CH4) production in man was first described by François Magendie (1783-
1855) in 1816 ([209], quoted in [210]). Methane is primarily produced by 
Methanobrevibacter smithii [211] and can be detected by breath sample 
measurements in about 35% of the population [212]. Approximately 108
methanogenic microbes per gram dry weight of feces are required to generate enough 
CH4 to be detected by breath analysis [213]. The overall impression from the present 
study is that methane is excreted rather independently of LDC ingestion. This 
probably reflects the fact that methanogenesis takes place mainly in the distal colon, 
and therefore depends more on endogenous than exogenous substrates [214]. 
Methane production has been associated with constipation [215], and measurement of 
exhaled methane has even been advocated as a diagnostic test for constipation-
predominant IBS [216]. A direct inhibitory effect of the gas on intestinal transit has 
been suggested, based on in vivo and in vitro experiments in dogs and guinea pigs 
[217]. Reduction of postprandial serotonin levels may be a mediating mechanism 
[218]. In addition, prolonged intestinal transit may increase methane production 
[219]. However, conflicting results have been published [220], and methane non-
producers and producers seemed to suffer equally from constipation in the present 
study (fig. 9 A). 
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Methane production may protect from symptoms following LDC ingestion [221]. An 
attractive explanation is that methanogenesis reduce the intraluminal gas volume by 
consuming H2, according to the reaction 4 H2 + CO2  CH4 + 2 H2O. However, as 
demonstrated by Morken et al. [196], methane producers actually have more gas 
present in their bowels after lactulose ingestion as compared to non-producers. 
Furthermore, methane producers were not protected from experiencing post-lactulose 
symptoms in the present study (fig. 9 B). Taken together, the clinical significance of 
methanogenesis in patients with unexplained, self-reported food hypersensitivity thus 
remains unclear. 
In study III, a dialysis technique was employed to assess the in vivo rectal 
concentrations of prostaglandin E2 (PGE2) and microbial fermentation products. The 
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rectum has previously been denoted as ”a window to IBS” [222], and increased levels 
of rectal PGE2 have been incriminated in patients with food-related IBS [223]. The 
approach of using rectal dialysis was also encouraged by the presence of symptoms 
suggestive of disturbed distal bowel functions in patients with unexplained, self-
reported food hypersensitivity, leading to the idea that the process of colonic 
fermentation may in part be distally displaced in these individuals. Indeed, 
preliminary work, using scintigraphy to assess gastrointestinal transit, indicated that a 
LDC-solution could reach the distal part of the colon rather quickly (fig. 10) 
[unpublished data]. 
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In retrospect, however, the interval between the ingestion of the carbohydrate 
solution and the insertion of the dialysis bag may have been too short. Levels of 
SCFA, lactate and PGE2 in rectal dialysates were not significantly different between 
the groups investigated in study III, and could thus not explain why lactulose 
ingestion evoked more symptoms in patients than in controls. 
Study V demonstrated alterations of the fecal SCFA profile in patients with 
unexplained, self-reported food hypersensitivity as compared to healthy controls. The 
observed SCFA pattern corroborates in part with data from other groups [224;225], 
but not all [226;227]. The discrepancy between study V and the studies of Tana et al. 
[226] and Morken et al. [227] may be explained by differences in pre-analytical 
sample handling. The work of Tana et al. [226] was commented upon in a ’Letter to 
the Editor’ in Neurogastroenterology and Motility, which is included in the 
Appendix. In the study of Morken et al. [227], the fecal samples were diluted with 
tap-water and homogenized before analysis, although this was not explicitly stated in 
their paper. Tana et al. [226] and Morken et al. [227] both showed increased levels of 
total SCFA in fecal samples from IBS patients as compared to healthy controls. These 
studies thus suggest that stool samples from IBS patients have a greater capacity to 
form microbial fermentation products in vitro. Interestingly, this characteristic was 
once considered as a pathognomic sign of ’Gährungsdyspepsie’ [26], and the ability 
of incubated fecal samples to produce excessive gas was used diagnostically [228]. 
Whether patients with IBS excrete more fermentable substrates than healthy controls 
would thus be interesting to investigate in future studies. 
The fecal SCFA profile observed in study V was characterized by increased 
proportions of butyric acid, particularly in patients with severe symptoms. This 
finding may have clinical implications, especially since butyrate has been shown to 
induce visceral hypersensitivity in rodents [229;230]. Intestinal fermentation of LDC 
by a microflora skewed to produce butyric acid may thus be a potential cause of LDC 
intolerance. At the same time, such a fermentation pattern conceivably offer 
protection against certain organic colorectal diseases [231;232]. Further studies are 
needed to clarify these aspects. 
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The gut microbial flora may adapt to dietary changes [233]. Indeed, this is the 
rationale for the use of prebiotics, defined by Gibson & Roberfroid as ”nondigestible 
food ingredients that beneficially affect the host by selectively stimulating the growth 
and/or activity of one or a limited number of bacteria in the colon, and thus improves 
host health” [234]. Many LDC possess a potential to change the composition and/or 
functions of the gut microbial flora, and may thus act as prebiotics [235]. 
Attractively, continuous intake of LDC may protect against LDC intolerance through 
colonic adaptation, as has been shown for lactose in individuals with hypolactasia 
[236]. However, conflicting results have been published [237], and the ability to 
induce symptomatic adaptation does not apply to all LDC [238-240]. Furthermore, 
the specificity of prebiotics has recently been questioned [241]. 
The idea that patients with IBS should eat more LDC has been prevailing for long. 
Partly motivated by religious beliefs, early health enthusiasts like Sylvester Graham 
(1794-1851), Sebastian Kneipp (1821-1897), Thomas Richard Allinson (1858-1918) 
and John Harvey Kellogg (1852-1943) recommended eating more ’roughage’ [43]. 
Coarse foods did not really become popular until the 1970s, however, when Denis 
Parsons Burkitt (1911-1993) hypothesized that most western diseases are caused by 
inadequate intake of dietary fiber [242]. Consequently, IBS was conceived as a 
disorder of fiber deficiency [243]. The effect of fiber on alleviating symptoms of IBS 
has, however, been extensively investigated and seems limited [244;245]. Soluble 
fibers, such as ispaghula or psyllium [246] and possibly soluble fibers contained 
within oatmeal porridge [247], may have positive effects. On the contrary, insoluble 
fibers seem to worsen the symptoms [248], and recent publications suggest that IBS 
patients actually benefit from reducing LDC intake [249;250]. Based on this evidence 
and on the results of the present papers, a study of the potential symptomatic effects 
of a LDC restricted diet in patients with unexplained, self-reported food 
hypersensitivity seems worthwhile. 
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6. Conclusions 
1. Intolerance to low-digestible carbohydrates is a common problem in patients with 
unexplained, self-reported food hypersensitivity. 
2. Carbohydrate malabsorption tests replicate habitual abdominal symptoms in 
patients with unexplained, self-reported food hypersensitivity. 
3. Abdominal symptoms following carbohydrate malabsorption in patients with 
unexplained, self-reported food hypersensitivity are not fully explained by 
symptom anticipation. 
4. Abdominal symptoms following carbohydrate malabsorption in patients with 
unexplained, self-reported food hypersensitivity are not correlated with intestinal 
gas production as assessed by breath sample measurements. 
5. Patients with unexplained, self-reported food hypersensitivity and healthy controls 
secrete similar amounts of glucagon-like peptide 1 and peptide YY following 
fructose-sorbitol ingestion. 
6. Patients with unexplained, self-reported food hypersensitivity have lower 
circulating levels of chromogranin A than healthy controls. 
7. Rectal levels of prostaglandin E2 are not significantly different between patients 
with unexplained, self-reported food hypersensitivity and healthy controls. 
8. Abnormal rectal fermentation do not seem to be a cause of symptoms following 
carbohydrate malabsorption in patients with unexplained, self-reported food 
hypersensitivity. 
9. Non-allergen-specific hypocontractility, increased levels of cytokines IL-4 and IL-
6 and high numbers of mast cells were demonstrated in the jejunum of food 
allergic mice, and may be involved in diarrhoea development. 
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10.Patients with unexplained, self-reported food hypersensitivity have a different 
profile of fecal short-chain fatty acids than healthy controls, indicating altered 
functions of the gut microbial flora that may be involved in abdominal symptom 
generation. 
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